Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

The historical lack of preclinical models reflecting the genetic heterogeneity of multiple myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this limitation, we screened mice engineered to carry eight MM lesions (NF-κB, KRAS, MYC, TP53, BCL2, cyclin D1, MMSET/NSD2 and c-MAF) combinatorially activated in B lymphocytes following T cell-driven immunization. Fifteen genetically diverse models developed bone marrow (BM) tumors fulfilling MM pathogenesis. Integrative analyses of ∼500 mice and ∼1,000 patients revealed a common MAPK-MYC genetic pathway that accelerated time to progression from precursor states across genetically heterogeneous MM. MYC-dependent time to progression conditioned immune evasion mechanisms that remodeled the BM microenvironment differently. Rapid MYC-driven progressors exhibited a high number of activated/exhausted CD8+ T cells with reduced immunosuppressive regulatory T (Treg) cells, while late MYC acquisition in slow progressors was associated with lower CD8+ T cell infiltration and more abundant Treg cells. Single-cell transcriptomics and functional assays defined a high ratio of CD8+ T cells versus Treg cells as a predictor of response to immune checkpoint blockade (ICB). In clinical series, high CD8+ T/Treg cell ratios underlie early progression in untreated smoldering MM, and correlated with early relapse in newly diagnosed patients with MM under Len/Dex therapy. In ICB-refractory MM models, increasing CD8+ T cell cytotoxicity or depleting Treg cells reversed immunotherapy resistance and yielded prolonged MM control. Our experimental models enable the correlation of MM genetic and immunological traits with preclinical therapy responses, which may inform the next-generation immunotherapy trials

Melanopsin as a Sleep Modulator: Circadian Gating of the Direct Effects of Light on Sleep and Altered Sleep Homeostasis in Opn4−/− Mice

Analyses in mice deficient for the blue-light-sensitive photopigment melanopsin show that direct effects of light on behavior and EEG depend on the time of day. The data further suggest an unexpected role for melanopsin in sleep homeostasis

Analysis of shared heritability in common disorders of the brain

ience, this issue p. eaap8757 Structured Abstract INTRODUCTION Brain disorders may exhibit shared symptoms and substantial epidemiological comorbidity, inciting debate about their etiologic overlap. However, detailed study of phenotypes with different ages of onset, severity, and presentation poses a considerable challenge. Recently developed heritability methods allow us to accurately measure correlation of genome-wide common variant risk between two phenotypes from pools of different individuals and assess how connected they, or at least their genetic risks, are on the genomic level. We used genome-wide association data for 265,218 patients and 784,643 control participants, as well as 17 phenotypes from a total of 1,191,588 individuals, to quantify the degree of overlap for genetic risk factors of 25 common brain disorders. RATIONALE Over the past century, the classification of brain disorders has evolved to reflect the medical and scientific communities' assessments of the presumed root causes of clinical phenomena such as behavioral change, loss of motor function, or alterations of consciousness. Directly observable phenomena (such as the presence of emboli, protein tangles, or unusual electrical activity patterns) generally define and separate neurological disorders from psychiatric disorders. Understanding the genetic underpinnings and categorical distinctions for brain disorders and related phenotypes may inform the search for their biological mechanisms. RESULTS Common variant risk for psychiatric disorders was shown to correlate significantly, especially among attention deficit hyperactivity disorder (ADHD), bipolar disorder, major depressive disorder (MDD), and schizophrenia. By contrast, neurological disorders appear more distinct from one another and from the psychiatric disorders, except for migraine, which was significantly correlated to ADHD, MDD, and Tourette syndrome. We demonstrate that, in the general population, the personality trait neuroticism is significantly correlated with almost every psychiatric disorder and migraine. We also identify significant genetic sharing between disorders and early life cognitive measures (e.g., years of education and college attainment) in the general population, demonstrating positive correlation with several psychiatric disorders (e.g., anorexia nervosa and bipolar disorder) and negative correlation with several neurological phenotypes (e.g., Alzheimer's disease and ischemic stroke), even though the latter are considered to result from specific processes that occur later in life. Extensive simulations were also performed to inform how statistical power, diagnostic misclassification, and phenotypic heterogeneity influence genetic correlations. CONCLUSION The high degree of genetic correlation among many of the psychiatric disorders adds further evidence that their current clinical boundaries do not reflect distinct underlying pathogenic processes, at least on the genetic level. This suggests a deeply interconnected nature for psychiatric disorders, in contrast to neurological disorders, and underscores the need to refine psychiatric diagnostics. Genetically informed analyses may provide important "scaffolding" to support such restructuring of psychiatric nosology, which likely requires incorporating many levels of information. By contrast, we find limited evidence for widespread common genetic risk sharing among neurological disorders or across neurological and psychiatric disorders. We show that both psychiatric and neurological disorders have robust correlations with cognitive and personality measures. Further study is needed to evaluate whether overlapping genetic contributions to psychiatric pathology may influence treatment choices. Ultimately, such developments may pave the way toward reduced heterogeneity and improved diagnosis and treatment of psychiatric disorders

Common variants in P2RY11 are associated with narcolepsy.

l e t t e r s Growing evidence supports the hypothesis that narcolepsy with cataplexy is an autoimmune disease. We here report genomewide association analyses for narcolepsy with replication and fine mapping across three ethnic groups (3,406 individuals of European ancestry, 2,414 Asians and 302 African Americans). We identify a SNP in the 3′ untranslated region of P2RY11, the purinergic receptor subtype P2Y 11 gene, which is associated with narcolepsy (rs2305795, combined P = 6.1 × 10 −10 , odds ratio = 1.28, 95% CI 1.19-1.39, n = 5689). The diseaseassociated allele is correlated with reduced expression of P2RY11 in CD8 + T lymphocytes (339% reduced, P = 0.003) and natural killer (NK) cells (P = 0.031), but not in other peripheral blood mononuclear cell types. The low expression variant is also associated with reduced P2RY11-mediated resistance to ATP-induced cell death in T lymphocytes (P = 0.0007) and natural killer cells (P = 0.001). These results identify P2RY11 as an important regulator of immune-cell survival, with possible implications in narcolepsy and other autoimmune diseases

Common variants in P2RY11 are associated with narcolepsy.

Growing evidence supports the hypothesis that narcolepsy with cataplexy is an autoimmune disease. We here report genome-wide association analyses for narcolepsy with replication and fine mapping across three ethnic groups (3,406 individuals of European ancestry, 2,414 Asians and 302 African Americans). We identify a SNP in the 3' untranslated region of P2RY11, the purinergic receptor subtype P2Y₁₁ gene, which is associated with narcolepsy (rs2305795, combined P = 6.1 × 10⁻¹⁰, odds ratio = 1.28, 95% CI 1.19-1.39, n = 5689). The disease-associated allele is correlated with reduced expression of P2RY11 in CD8(+) T lymphocytes (339% reduced, P = 0.003) and natural killer (NK) cells (P = 0.031), but not in other peripheral blood mononuclear cell types. The low expression variant is also associated with reduced P2RY11-mediated resistance to ATP-induced cell death in T lymphocytes (P = 0.0007) and natural killer cells (P = 0.001). These results identify P2RY11 as an important regulator of immune-cell survival, with possible implications in narcolepsy and other autoimmune diseases.journal articleresearch support, n.i.h., extramuralresearch support, non-u.s. gov'tresearch support, u.s. gov't, p.h.s.2011 Jan2010 12 19importedErratum in : Nat Genet. 2011 Oct;43(10):1040

Influence non-circadienne de la lumière sur les comportements : identification des structures impliquées et application clinique

Light influences physiology and behavior through both types of non-image-forming effects: i) indirect, synchronizing the circadian master clock located in the suprachiasmatic nucleus (SCN), ii) direct effects, independent from the circadian process though mechanisms poorly understood. Our studies in mice demonstrate that the direct influence of light constitutes a key mechanism of regulation for sleep, alertness and mood and is as important as the circadian process. The direct effects of light are mainly mediated through melanopsin, a retinal photopigment that projects to the different structures of the brain such as the SCN and the VLPO. The SCN, beyond their role as circadian clock are also a relay system for the direct effects of light. Further, we validated Arvicanthis ansorgei as a diurnal model for the study of sleep regulatory mechanisms. This is an important step in the translational approach from animal research to applications in humans. Various data suggest that the direct effects of light interact with the dopaminergic system. In the last part of this thesis, we evaluated the indication of bright light therapy in dopaminergic pathologies (Parkinson disease, restless legs syndrome, mood disorders). These advances open up new perspectives for possible applications of light therapy and may help improving societal lightening conditions.La lumière influence fortement la physiologie et le comportement en exerçant des effets non-visuels de deux types : i) indirects, via la resynchronisation de l’horloge centrale qui est située dans les noyaux suprachiasmatiques (NSC), ii) directs, indépendants du processus circadien, via des mécanismes encore mal compris. Nos travaux chez la souris ont montré que l’influence directe de la lumière constitue un mécanisme majeur de régulation du sommeil, de l’éveil et de l’humeur, au même titre que le processus circadien. Ces effets sont majoritairement médiés par la mélanopsine, un photopigment exprimé dans la rétine, et relayés au niveau cérébral par différentes structures comme les NSCs et le VLPO. Ainsi, le rôle des NSCs ne doit pas être interprété qu’au travers de leur fonction d’horloge. Ensuite, dans une perspective de recherche translationnelle de l’animal à l’homme, nous avons validé Arvicanthis ansorgei, comme modèle d’étude du sommeil afin de pouvoir interpréter nos résultats chez un rongeur diurne. Enfin, de nombreuses données suggérant que les effets directs de la lumière modulent l’activité du système dopaminergique, nous avons évalué l’intérêt de la luminothérapie dans des pathologies dopaminergiques (maladie de Parkinson, syndrome des jambes sans repos, troubles de l’humeur). Ces avancées ouvrent de nombreuses perspectives pour une meilleure utilisation de la lumière dans notre société ainsi qu’en pathologie

Non-circadian influence of light on behavior : identification of implicated structures and clinical application

La lumière influence fortement la physiologie et le comportement en exerçant des effets non-visuels de deux types : i) indirects, via la resynchronisation de l’horloge centrale qui est située dans les noyaux suprachiasmatiques (NSC), ii) directs, indépendants du processus circadien, via des mécanismes encore mal compris. Nos travaux chez la souris ont montré que l’influence directe de la lumière constitue un mécanisme majeur de régulation du sommeil, de l’éveil et de l’humeur, au même titre que le processus circadien. Ces effets sont majoritairement médiés par la mélanopsine, un photopigment exprimé dans la rétine, et relayés au niveau cérébral par différentes structures comme les NSCs et le VLPO. Ainsi, le rôle des NSCs ne doit pas être interprété qu’au travers de leur fonction d’horloge. Ensuite, dans une perspective de recherche translationnelle de l’animal à l’homme, nous avons validé Arvicanthis ansorgei, comme modèle d’étude du sommeil afin de pouvoir interpréter nos résultats chez un rongeur diurne. Enfin, de nombreuses données suggérant que les effets directs de la lumière modulent l’activité du système dopaminergique, nous avons évalué l’intérêt de la luminothérapie dans des pathologies dopaminergiques (maladie de Parkinson, syndrome des jambes sans repos, troubles de l’humeur). Ces avancées ouvrent de nombreuses perspectives pour une meilleure utilisation de la lumière dans notre société ainsi qu’en pathologie.Light influences physiology and behavior through both types of non-image-forming effects: i) indirect, synchronizing the circadian master clock located in the suprachiasmatic nucleus (SCN), ii) direct effects, independent from the circadian process though mechanisms poorly understood. Our studies in mice demonstrate that the direct influence of light constitutes a key mechanism of regulation for sleep, alertness and mood and is as important as the circadian process. The direct effects of light are mainly mediated through melanopsin, a retinal photopigment that projects to the different structures of the brain such as the SCN and the VLPO. The SCN, beyond their role as circadian clock are also a relay system for the direct effects of light. Further, we validated Arvicanthis ansorgei as a diurnal model for the study of sleep regulatory mechanisms. This is an important step in the translational approach from animal research to applications in humans. Various data suggest that the direct effects of light interact with the dopaminergic system. In the last part of this thesis, we evaluated the indication of bright light therapy in dopaminergic pathologies (Parkinson disease, restless legs syndrome, mood disorders). These advances open up new perspectives for possible applications of light therapy and may help improving societal lightening conditions